Cancer immunotherapy is a category of treatments that harness the body’s own immune system to find and destroy cancer cells, and it has reshaped oncology over the past two decades. The field stretches back more than a century, but the modern era took off with the development of immune checkpoint inhibitors and, more recently, engineered cell therapies that have produced durable remissions in cancers once considered untreatable. Understanding what immunotherapy actually does, who it helps, and where it falls short requires a closer look at several distinct approaches, each with its own strengths and limitations.
A Brief Origin Story
The idea of turning the immune system against cancer is older than most people realize. In the 1890s, a surgeon named William Coley injected cancer patients with a cocktail of heat-killed bacteria, hoping to trigger an immune response strong enough to shrink tumors. His results were inconsistent and met with skepticism, but the underlying concept proved prophetic.
1PubMed Central. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy The mid-twentieth century brought cytokine therapies like interferons and interleukins, which showed that manipulating the immune response could shrink tumors, though side effects were harsh and responses unpredictable. The real breakthroughs arrived with the discovery of immune checkpoints, regulatory switches that normally prevent the immune system from attacking the body’s own tissues but that cancer cells hijack to hide from immune detection.2PubMed Central. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives
How Checkpoint Inhibitors Work
Your immune system has built-in brakes. Proteins like PD-1 on T cells and PD-L1 on other cells act as a handshake that tells the immune system to stand down. This is normally useful: without those brakes, your T cells would attack healthy tissue. But many cancers learn to display PD-L1 on their surface, essentially waving a fake badge that tells approaching T cells to move along. Checkpoint inhibitors are drugs, typically antibodies, that block this handshake. When a PD-1 or PD-L1 inhibitor prevents the two proteins from connecting, the T cells can recognize and attack the tumor.
A similar strategy targets a different checkpoint called CTLA-4, which dials down immune activation at an earlier stage. Blocking CTLA-4 releases those earlier brakes, allowing a broader immune response to develop. Together, PD-1/PD-L1 and CTLA-4 inhibitors have produced responses across a wide range of cancers, though challenges like immune resistance remain an active area of research.3PubMed Central. Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1 Checkpoint inhibitors are now approved for melanoma, lung cancer, bladder cancer, kidney cancer, and many others, and they represent the most widely used class of immunotherapy today.
CAR-T Cell Therapy
Where checkpoint inhibitors remove the brakes from existing T cells, CAR-T therapy builds custom weapons. The process starts by drawing blood from a patient and extracting their T cells. Those cells are then genetically modified in a lab to carry a chimeric antigen receptor, a synthetic sensor designed to lock onto a specific protein found on the patient’s cancer cells. After the modified cells multiply, they are infused back into the patient, where they hunt for anything displaying that target protein.
CAR-T therapy has produced remarkable results in certain blood cancers, including some types of leukemia and lymphoma, particularly in patients whose disease had stopped responding to chemotherapy.4PubMed Central. Challenges and strategies associated with CAR-T cell therapy in blood malignancies The results in solid tumors, however, have been far less impressive. Solid tumors present a different kind of problem: they build a local environment around themselves that actively suppresses immune cells, and they often lack a single distinctive protein on their surface that CAR-T cells can reliably target. Physical barriers within the tumor also prevent the engineered cells from reaching cancer cells deep inside the mass.5PubMed Central. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions The gap between what CAR-T achieves in blood cancers and what it can do in solid tumors is one of the field’s central unsolved problems.6PubMed Central. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Tumor-Infiltrating Lymphocytes and CAR-NK Cells
CAR-T is not the only approach to engineering immune cells against cancer. Tumor-infiltrating lymphocyte (TIL) therapy takes a different route: rather than building a custom receptor from scratch, researchers harvest immune cells that have already migrated into a patient’s tumor, expand them in the lab, and infuse them back in large numbers. Because these cells were already drawn to the tumor naturally, they tend to recognize features that are genuinely specific to the cancer. TIL therapy has shown strong results in advanced solid tumors, particularly melanoma, and research suggests that cancers with higher numbers of mutations may respond well to bulk TIL infusions, while tumors with fewer mutations may need a more curated selection of the most tumor-reactive cells.7Visualized Cancer Medicine. Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects8PubMed Central. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
Meanwhile, researchers are also exploring CAR-NK cells, which apply the chimeric receptor concept to natural killer cells instead of T cells. Early studies are promising in part because CAR-NK cells appear to cause fewer of the severe inflammatory side effects associated with CAR-T, such as cytokine release syndrome and neurotoxicity.9Journal of Hematology & Oncology (PubMed Central). Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy Whether CAR-NK cells will ultimately match CAR-T in effectiveness remains to be seen, but the early safety profile is encouraging enough to keep clinical development moving forward.
Cancer Vaccines and Oncolytic Viruses
Unlike the vaccines most people think of, which prevent infections, therapeutic cancer vaccines are designed to treat existing disease. The idea is to train the immune system to recognize proteins found specifically on a patient’s tumor. One of the most active areas of research involves mRNA-based neoantigen vaccines, which use the same mRNA platform that became familiar during the COVID-19 pandemic. Researchers sequence a patient’s tumor to identify unique mutations, then design an mRNA vaccine encoding those mutations. When injected, the vaccine teaches the patient’s immune cells to recognize and attack cells carrying those mutant proteins. Early clinical studies in melanoma and non-small cell lung cancer have shown that these vaccines can expand populations of tumor-reactive T cells and improve recurrence-free outcomes, especially when combined with checkpoint inhibitors.10PubMed Central. Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy
Oncolytic viruses take a completely different angle. These are viruses, either naturally occurring or genetically engineered, that selectively infect and destroy cancer cells while leaving normal tissue alone. As the virus replicates inside the tumor and kills cancer cells, it also releases tumor antigens that prime the immune system to mount a broader attack. A phase III trial in advanced melanoma demonstrated that an engineered herpes virus called T-Vec, injected directly into tumors, could suppress growth at the injection site and also produce systemic effects that prolonged overall survival.11PubMed Central. Oncolytic virus therapy: A new era of cancer treatment at dawn
Bispecific Antibodies
Bispecific T-cell engagers, often called BiTEs, are a class of engineered molecules with two arms. One arm grabs onto a T cell by binding CD3, a protein on the T cell’s surface. The other arm grabs a protein found on the tumor cell. By physically bridging a T cell and a cancer cell, BiTEs force the two into close contact and trigger the T cell to activate and kill the cancer cell.12PubMed Central. Bispecific T-cell engagers for cancer immunotherapy Unlike CAR-T therapy, bispecific antibodies are off-the-shelf drugs that do not require manufacturing a custom product for each patient, which makes them faster to administer and potentially cheaper. They have gained approvals in certain blood cancers, and trials are testing them across a wider range of tumor types.
Why Immunotherapy Does Not Work for Everyone
For all the headline-grabbing success stories, the reality is that most cancer patients either do not respond to immunotherapy or eventually develop resistance after an initial response.13PubMed Central. Mechanisms of Cancer Resistance to Immunotherapy Understanding why requires looking at the tumor itself. Researchers often divide tumors into “hot” and “cold” categories. Hot tumors are already packed with immune cells and surrounded by inflammatory signals, which means checkpoint inhibitors have raw material to work with. Cold tumors, by contrast, have very few immune cells inside them and maintain an environment that actively suppresses immune activity, effectively hiding from detection.14PubMed Central. Turning cold tumors into hot tumors to ignite immunotherapy Many of the most treatment-resistant cancers, including certain pancreatic and brain tumors, are cold.
Even in patients who initially respond, resistance can develop. This may be “primary,” meaning the treatment never worked in the first place, or “secondary,” where the cancer relapses after an initial period of control.15PubMed Central. Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives Several mechanisms drive this. Tumors can lose the ability to display their internal proteins on their surface, essentially going invisible to T cells. They can also alter signaling pathways. The interferon-gamma pathway, which normally helps immune cells kill cancer, has emerged as a key player in multiple forms of resistance: tumors that shut down this pathway become harder to detect and kill.16Cell. Resistance Mechanisms to Immune-Checkpoints and Adoptive Cell Transfer
Predicting Who Will Respond
Because immunotherapy works for some patients and not others, there is enormous interest in finding biomarkers that can predict who will benefit. The two most established are PD-L1 expression, which measures how much of the target protein a tumor displays, and microsatellite instability-high (MSI-H), a condition where the tumor’s DNA repair machinery is broken, leading to many mutations that the immune system can recognize. Both have clinical utility, but neither is perfect: some patients with low PD-L1 still respond, and some with high PD-L1 do not.17PubMed Central. Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors
Tumor mutational burden (TMB), which counts the total number of mutations in a tumor’s DNA, has also shown value as a predictor of response to checkpoint inhibitors across multiple cancer types.18Acta Pharmacologica Sinica. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors The logic is straightforward: more mutations mean more abnormal proteins on the cell surface, which gives the immune system more targets. But TMB alone is still not reliable enough to make treatment decisions for individual patients, and researchers are actively searching for better composite biomarkers that combine multiple signals.
Side Effects of Unleashing the Immune System
Removing the brakes from the immune system does not just affect cancer cells. Immune-related adverse events can affect virtually any organ, because the same T cells that attack a tumor can also turn on healthy tissue. The most common side effects involve the skin, the gut, and the endocrine system. Rashes, colitis (inflammation of the colon), and thyroid dysfunction come up frequently. Less common but potentially serious effects include inflammation of the heart, lungs, or nervous system.19PubMed Central. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
The pattern of side effects differs by drug class. CTLA-4 inhibitors tend to cause more gut toxicity and pituitary gland inflammation, while PD-1/PD-L1 inhibitors are more associated with thyroid problems and lung inflammation. Management follows a graded approach: mild reactions are monitored while continuing treatment; moderate reactions may prompt a temporary pause and possibly corticosteroids; severe reactions generally require stopping the drug and starting high-dose steroids, tapered over at least four to six weeks. The rarest but most dangerous complications, such as heart inflammation, usually warrant permanent discontinuation, with the exception of hormone-related side effects that can be managed with replacement therapy.20PubMed. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
The Gut Microbiome Connection
One of the more surprising discoveries in recent years is that the bacteria living in your gut may influence how well immunotherapy works. Multiple studies have found that the composition of the gut microbiome correlates with both the likelihood of responding to checkpoint inhibitors and the risk of developing immune-related side effects.21PubMed Central. The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions Specific bacterial community structures, species compositions, and even functional profiles have been identified as potential biomarkers for predicting immunotherapy outcomes.22PubMed Central. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
This has opened the door to interventions like fecal microbiota transplants from patients who responded well to immunotherapy into patients who did not, and early results from small clinical trials have been intriguing. The field is still young, and nobody is ready to prescribe a probiotic regimen as part of cancer treatment. But the microbiome is increasingly seen not just as a bystander but as an active player that can be shaped to improve treatment outcomes.
Combining Immunotherapy with Radiation and Other Treatments
Immunotherapy is increasingly being paired with other treatments, and the combination with radiation therapy may be one of the most logical pairings. When radiation kills cancer cells, it scatters their contents into the surrounding tissue, effectively spilling a bag of tumor proteins that the immune system can learn to recognize. Radiation also increases the display of PD-L1 on tumor cells and draws more immune cells into the tumor, potentially converting a cold tumor into something warmer and more responsive to checkpoint blockade.23PubMed Central. Radiation and immunotherapy: emerging mechanisms of synergy Preclinical data and early clinical experience support the idea that these two approaches are genuinely synergistic rather than merely additive.24The Lancet Oncology. Radiation and immunotherapy: a synergistic combination
Epigenetic drugs are another promising combination partner. These agents modify how genes are read without changing the DNA sequence itself. When cancer cells silence certain genes to hide from the immune system, epigenetic drugs can reverse that silencing, forcing the tumor to display antigens that make it visible again. In preclinical models, a DNA demethylating agent given before PD-1 blockade reversed the exhaustion-related DNA changes in T cells and promoted expansion of tumor-reactive immune cells, resulting in better tumor control than either approach alone.25PubMed Central. Epigenetic modulation of immunotherapy and implications in head and neck cancer Epigenetic agents can also coax tumors into expressing proteins they had been hiding and trigger a type of cell death that releases a flood of immunogenic material, priming stronger immune responses.26PubMed Central. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Why Immunotherapy Has Struggled in Children
Checkpoint inhibitors have transformed treatment for many adult cancers, but initial trials in children have been largely disappointing. With the exception of pediatric Hodgkin lymphoma, responses to single-agent checkpoint inhibitors in unselected childhood cancers have been infrequent.27PubMed. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again The reason likely comes down to biology: childhood cancers tend to carry far fewer mutations than adult cancers, which means they present fewer neoantigens for the immune system to latch onto. In other words, many pediatric tumors are inherently cold. This does not mean immunotherapy has no role in pediatric oncology. CAR-T therapy, for instance, has been transformative for certain pediatric leukemias. But the checkpoint inhibitor revolution that swept through adult oncology has not translated as broadly to children, and the field is actively working on strategies better suited to the lower mutational landscape of childhood tumors.
The Cost and Access Problem
Even when immunotherapy works, getting it to patients is not straightforward. CAR-T therapy, for example, remains extraordinarily expensive, and the manufacturing process is complex: each treatment is custom-built from a single patient’s cells, requiring specialized facilities and weeks of production time.28PubMed. High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions The current centralized manufacturing model strains resources even in wealthy countries, and patient access is effectively impossible in much of the developing world.29PubMed Central. Promises and challenges of a decentralized CAR T-cell manufacturing model Infrastructure requirements, from apheresis centers to specialized intensive care units for managing complications, present additional barriers in regions with less developed healthcare systems.30PubMed Central. Challenges in Global Access to CAR-T cells: an Asian Perspective
Decentralized manufacturing, where CAR-T cells would be produced at or near the treatment hospital rather than shipped across continents, is one proposed solution. Off-the-shelf therapies like bispecific antibodies and, potentially, CAR-NK cells could also help close the access gap by eliminating the need for patient-specific manufacturing. But for now, the most advanced forms of cancer immunotherapy remain concentrated in high-income countries with large academic medical centers.
What Pet Dogs Are Teaching Cancer Researchers
One of the more unexpected chapters in immunotherapy research involves pet dogs. Dogs develop spontaneous cancers at rates roughly comparable to humans, and their tumors arise in the context of a fully intact, naturally educated immune system, something lab mice cannot replicate. The canine immune system is similar enough to the human one that researchers can test checkpoint antibodies, tumor vaccines, cell-based therapies, and combination regimens in dogs with naturally occurring cancers and generate data more predictive of what will happen in human trials.31PubMed Central. Comparative oncology in action: vignettes on immunotherapy development This field, called comparative oncology, provides a middle step between mouse experiments and human clinical trials, capturing complexities like tumor heterogeneity and immune evasion that mouse models often miss.32Journal for ImmunoTherapy of Cancer. Canine cancer immunotherapy studies: linking mouse and human
Studies in dogs have already contributed to the development of vaccines targeting specific tumor-associated antigens, and results from canine trials have informed the design of subsequent human studies.33PubMed Central. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy The arrangement benefits the dogs, too: participating animals receive cutting-edge treatment for their cancers that would not otherwise be available. It is a genuinely symbiotic research model, and one that is gaining traction as immunotherapy strategies grow more complex and harder to evaluate in traditional preclinical settings.